Hepatitis B Treatment Market- Highlight:
Hepatitis B is a lethal infection that can be developed if the hepatitis B virus or HBV enters the body. It attacks the liver and can lead to liver diseases such as cirrhosis or liver cancer. The rising awareness about the diseases is likely to catalyze the demand for treatment in the forthcoming years. As per Market Research Future (MRFR)’s assessment, the global hepatitis B treatment market is expected to mark a CAGR of 5.3% during the forecast period 2018 to 2024.
FREE SAMPLE COPY OF Hepatitis B Treatment Market Research Report- Global forecast till 2023” @https://www.marketresearchfuture.com/sample_request/7817
The World Health Organization (WHO)’s assessment reveals that approximately 257 million people currently have hepatitis B. The statistical observation further reveals that 887,000 patients lost lives to the disease in 2015. The increasing prevalence of the diseases is anticipated to accelerate the revenue growth of the hepatitis B treatment market over the next couple of years.
Awareness campaigns organized by governments and national & international organizations are anticipated to boost the growth pattern of the hepatitis B treatment market. In addition, factors such as increasing healthcare expenditure, developments in the healthcare sector, etc. are expected to have a favorable impact on the market’s pace of expansion. On the flip side, the adverse effects of the treatment can pose a challenge to market players.
Hepatitis B Treatment Market- Competitive Analysis
The players operating in the global hepatitis B treatment market and profiled in this MRFR report are
- Apotex Corp
- Accord Healthcare
- Arbutus Biopharma
- Aurobindo Pharma Limited
- Arrowhead Pharma
- Bristol-Myers Squibb Company
- Gilead Sciences
- Lupin Pharmaceuticals
- Par Pharmaceutical
- Merck & Co
- Teva Pharmaceuticals,
- Zydus Pharmaceuticals.
and Many More…
Hepatitis B Treatment Market- Segmental Analysis:
Based on type, the global hepatitis B treatment market has been bifurcated into acute and chronic.
By treatment, the hepatitis B treatment market has been segmented into antiviral drugs, vaccine, immune modulator drugs, and surgery (liver transplant). The immune modulator drugs segment has been further sub-divided into pegylated interferon and interferon alpha. The antiviral drugs segment has been sub-segmented into entecavir, telbivudine, tenofovir disoproxil, lamivudine, and others.
On the basis of distribution channel, the global hepatitis B treatment market has been bifurcated into hospital & retail pharmacies and online pharmacies.
Hepatitis B Treatment Market- Detailed Regional Analysis
By region, the global hepatitis B treatment market has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is anticipated to lead the growth pattern of the global market. Increasing investments in clinical trials for finding effective vaccines or cure is projected to influence the expansion of the regional market positively in the years to come.
Europe is likely to maintain its second spot over the next few years. The factors contributing towards the development of hepatitis B treatment market in the region include rising research & development projects, increasing healthcare expenditure, etc. Also, the increasing awareness being observed in the region is poised to support the growth rate of the market.
Asia Pacific is projected to market a comparatively higher CAGR over the review period. The presence of a developing medical diagnostic sector is likely to encourage the expansion of the hepatitis B treatment market in the region.
In May 2019, Abivax, a clinical-stage biotechnology company, and Scripps Research, an American medical research facility, has received FDA approval for initiating Phase 1/2 Clinical Trial with ABX196 in patients suffering from Hepatocellular Carcinoma (HCC) which is closely linked with hepatitis B or C infection.
In May 2019, Dicerna Pharmaceuticals, the leader in innovative RNAi therapies, has announced the commencement of investigational therapeutic DCR-HBVS in patients with chronic hepatitis B virus (HBV) infection.
In May 2019, Dynavax Technologies Corporation, a biopharmaceutical company, announced its strategic restructuring to focus on its vaccine business, especially its first commercial product, the hepatitis B vaccine, HEPLISAV-B®.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312